Pricing Log in Create free account
Saturday 17 October 2026 Export ZVRA’s income statement to Excel — free account

Zevra Therapeutics, Inc.

ZVRA Healthcare Biotechnology

Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.

9.95 0.32 −3.12%
Market cap
$609.9M
P/E
10.5×
Fwd P/E
10.5×
Dividend yield
—
F-score
6/9
Altman Z
0.63
Beneish M
1.46
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.52
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — 4 4 — — 1 1 — 2 — 1
Insider Ownership 0.89%

Capital & Financial Ratios $m

Market Cap 609.88
Revenue 136.07
Net Income 58.26
Free Cash Flow 33.07
Net Debt (221.57)
Current Ratio 5.17 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 10.47
Fwd P/E 10.50
P/S ratio 4.33
P/B ratio 2.70
Past 5Y EPS Growth —
This Y EPS Growth (17.88%) (below 0%: weak)
Next Y EPS Growth (15.57%) (below 0%: weak)
Next Y revenue growth 43.98% (at or above 10%: strong)
Next 5Y EPS Growth 1.47%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.4×, against a ten-year median of 7.0×; over the ten years it ranged from 2.3× in 2022 to 18.5× in 2024.
P/S against its own 10 years 10.80%
10-year low 10-year high
P/B against its own 10 years 44.38%
10-year low 10-year high
EV/Sales against its own 10 years 6.70%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 68 69 191 222
Receivables 17 11 23 22
Inventory — 2 2 2
Other — — — —
87 86 223 251
2023 2024 2025 Q'26
Payables 28 25 12 14
ST’ Debt 38 — — —
Other 7 8 14 13
74 34 39 49

Compound Annual Growth %

10y 5y 3y
Sales — 51.62% 118.82%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 27.21%

Revenue $m

Mar Jun Sep Dec Year
’26 36 40 — — —
’25 20 26 26 34 106
’24 3 4 4 12 24
’23 3 8 3 13 27
’22 4 1 3 2 10
’21 12 12 2 3 29
’20 2 7 2 2 13
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 6 17 — — —
’25 (8) (4) 5 6 (2)
’24 (16) (19) (18) (16) (70)
’23 (4) (9) (5) (16) (34)
’22 (4) (4) (7) (4) (19)
’21 (3) 17 (3) (1) 10
’20 (2) 2 (1) (1) (2)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 50 22 — — —
’25 (8) (4) 5 5 (2)
’24 (16) (19) (18) (16) (70)
’23 (4) (9) (5) (16) (34)
’22 (4) (4) (7) (4) (19)
’21 (3) 17 (3) (1) 10
’20 (2) 2 (1) (1) (2)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.60 0.14 — — —
’25 (0.06) 1.21 (0.01) 0.19 1.35
’24 (0.40) (0.48) (0.69) (0.67) (2.28)
’23 (0.34) (0.08) (0.30) (0.54) (1.30)
’22 (0.05) (0.70) (0.19) 0.17 (0.78)
’21 (2.49) (0.40) (0.06) 0.09 (2.11)
’20 (1.92) 0.16 (0.64) (0.83) (3.21)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 46.40 39.20 27.44 4.24 1.94 5.08 4.00 3.89 4.20 6.19

Analyst estimates 2026–2028

Powerpack
High 316.00 86.40 134.40 45.60 22.08 18.15 9.43 6.68 9.76 13.16
People
People Employees 32 32 33 22 22 24 36 69 59 61
Revenue/emp, $m 0.00 0.00 0.00 0.58 0.60 1.19 0.28 0.40 0.40 1.75
Income, $m
Income, $m Revenue — — — 13 13 29 10 27 24 106
Gross margin, % 0.00 0.00 0.00 77.06 90.18 92.81 97.82 92.09 68.59 84.52
EBT (17) (43) (57) (25) (13) (9) (27) (46) (90) 87
EBT margin, % 0.00 0.00 0.00 (191.17) (96.28) (29.74) (263.80) (167.69) (381.76) 81.41
Net income (17) (43) (56) (25) (13) (9) (27) (46) (106) 83
Depreciation 2 2 2 2 3 0 1 1 5 60
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 6.93 3.34 0.96 0.29 0.77 0.51 1.92
Earnings (18.08) (47.36) (50.40) (13.28) (3.21) (2.11) (0.78) (1.30) (2.28) 1.40
Cash flow (32.63) (36.14) (48.37) (12.81) (0.49) 0.35 (0.54) (0.95) (1.51) (0.03)
Capex (0.70) (0.20) (0.02) (0.01) (0.01) 0.00 0.00 (0.01) 0.00 (0.01)
Free cash flow (33.34) (36.34) (48.39) (12.82) (0.50) 0.35 (0.55) (0.95) (1.51) (0.04)
Book value (20.49) (62.80) (59.40) (40.18) (16.68) 4.27 2.18 1.75 0.86 2.80
Shares, m 1 1 1 2 4 30 34 35 46 55
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 6.54
P/S — — — 0.00 3.36 9.05 15.38 8.82 16.34 4.65
P/B — — — 0.00 0.00 2.04 2.08 3.91 9.72 3.20
EV/Sales — — — 0.00 8.18 5.18 8.53 7.91 17.51 3.80
EV/FCF — — — (3.60) (55.12) 14.40 (4.61) (6.42) (5.91) (203.63)
Cash, $m
Cash, $m Operating cash flow (30) (33) (54) (24) (2) 10 (19) (34) (70) (2)
Capex (1) 0 0 0 0 0 0 0 — 0
Free cash flow (30) (33) (54) (24) (2) 10 (19) (34) (70) (2)
Balance, $m
Balance, $m Working capital 68 34 12 2 1 111 81 13 52 184
Total debt 92 93 82 78 68 2 13 43 60 62
Net debt 23 51 60 74 64 (111) (70) (25) (10) (129)
Shareholders’ equity (19) (58) (67) (74) (66) 127 75 62 40 155
Returns, %
Returns, % ROA (23.68) (63.18) (142.59) (131.65) (117.52) (87.27) (21.57) (32.02) (60.21) 33.52
ROIC (529.65) 0.00 0.00 0.00 0.00 29.49 (478.56) (84.03) (183.25) (153.83)
ROE 114.63 113.86 91.01 34.78 18.12 (207.22) (26.48) (67.23) (207.84) 79.85
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Zevra Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
WVE WAVE Life Sciences Ltd. $628.6M — (loss-making) — (loss-making) −73.88% (below 0%: shrinking) n/m −17.59% (below 0%: shrinking) 100.00% (3,248.33%) Compare
CLYM Climb Bio, Inc. $626.6M — (loss-making) — — n/m +3.73% (above 0%: growing) — 0.00% Compare
NVCT Nuvectis Pharma, Inc. $618.0M — (loss-making) — — n/m −34.57% (below 0%: shrinking) — 0.00% Compare
SLDB Solid Biosciences Inc. $615.5M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −39.56% (below 0%: shrinking) 0.00% 0.00% Compare
ZVRA Zevra Therapeutics, Inc. $609.9M 10.5× 10.5× +53.25% (above 0%: growing) −88.71% (below 0%: shrinking) +670.87% (above 0%: growing) 96.16% 42.30%
PHAT Phathom Pharmaceuticals, Inc. $606.8M — (loss-making) — (loss-making) +88.02% (above 0%: growing) n/m +96.86% (above 0%: growing) 79.68% (5.34%) Compare
OLMA Olema Pharmaceuticals, Inc. $601.1M — (loss-making) — — n/m −54.33% (below 0%: shrinking) 0.00% 0.00% Compare
CRMD CorMedix Inc $581.5M 3.0× 16.5× +156.52% (above 0%: growing) +13.79% (above 0%: growing) +185.90% (above 0%: growing) 75.66% 42.10% Compare
SLN Silence Therapeutics PLC Sponsored ADR $581.1M — (loss-making) — (loss-making) +197.18% (above 0%: growing) n/m +106.95% (above 0%: growing) 97.39% 0.00% Compare
Median of peers $611.1M — — +88.02% — −6.93% 77.67% 0.00%

All 614 Biotechnology stocks →

Zevra Therapeutics, Inc. (ZVRA) key facts

  • Strength: Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024.
  • Zevra Therapeutics, Inc. (ZVRA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ZVRA traded at $9.95, a market capitalization of $609.9 million.
  • Return on equity was 79.9% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.63 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Zevra Therapeutics, Inc. (ZVRA) Latest News

20 Sep

Impact 5 ·
stockrow.com/ZVRA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com